Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a trial of XEN-D0501 in idiopathic overactive bladder
2010-022611-19Phase 2Completed
- Sponsor
- Xention Ltd.
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of XEN-D0501 in overactive bladder (OAB) (3 arms), sponsored by Xention Ltd. Primary endpoint: Change in voids per 24 hours. Started Nov 2010; status: completed.
02
Drugs
XEN-D0501
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2010-022611-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022611-19.